Quick Answer
Damora Therapeutics, Inc. reported Net Income of -$209.84 million for fiscal year 2025.
Damora Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$209.84M -878.8% |
-$21.44M +44.1% |
-$38.35M +37.8% |
-$61.62M -19.1% |
-$51.75M -48.6% |
-$34.84M +4.6% |
| Diluted EPS | $3.98 +121.5% |
-$18.53 +48.6% |
-$36.08 -1384.8% |
-$2.43 -18.5% |
-$2.05 | — |
| Total Assets | $260.53M +1420.7% |
$17.13M -55.2% |
$38.23M -47.8% |
$73.19M -40.1% |
$122.22M -28.8% |
$171.60M +203.1% |
| Cash and Equivalents | $257.62M +1717.5% |
$14.18M -34.0% |
$21.46M -34.5% |
$32.79M -47.6% |
$62.56M -61.8% |
$163.58M +1348.4% |
| Stockholders Equity | $240.38M +1418.4% |
$15.83M -51.0% |
$32.33M -47.6% |
$61.75M -47.3% |
$117.22M -29.2% |
$165.49M +332.6% |
| R&D Expense | $26.88M +320.1% |
$6.40M -73.1% |
$23.77M -50.7% |
$48.21M +25.2% |
$38.49M +56.3% |
$24.63M +24.8% |
| Operating Income | -$210.87M -847.3% |
-$22.26M +44.2% |
-$39.91M +34.8% |
-$61.21M -17.2% |
-$52.23M -55.3% |
-$33.64M -186.3% |
| Shares Outstanding | 1.60M +21.3% |
1.32M +21.4% |
1.08M -95.8% |
25.65M +1.5% |
25.26M +0.0% |
25.26M +9617.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.13M | +19.3% | +8.8% |
| Diluted EPS | September 30, 2025 | -$2.36 | +30.4% | +9.2% |
| Total Assets | September 30, 2025 | $10.74M | -54.1% | -21.6% |
| Cash and Equivalents | September 30, 2025 | $7.61M | -61.3% | -25.5% |
| Stockholders Equity | September 30, 2025 | $8.01M | -61.8% | -26.9% |
| R&D Expense | September 30, 2025 | $1.42M | +29.6% | -3.3% |
| Operating Income | September 30, 2025 | -$3.16M | +17.8% | +7.7% |
| Shares Outstanding | September 30, 2025 | 1.33M | +5.9% | +0.2% |
- Damora Therapeutics, Inc. reported Net Income of -$209.84 million for fiscal year 2025.
- Damora Therapeutics, Inc. showed a decrease of -878.8% in Net Income compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported Diluted EPS of $3.98 per share for fiscal year 2025.
- Damora Therapeutics, Inc. showed an increase of +121.5% in Diluted EPS compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported Total Assets of $260.53 million for fiscal year 2025.
- Damora Therapeutics, Inc. showed an increase of +1420.7% in Total Assets compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported Cash and Equivalents of $257.62 million for fiscal year 2025.
- Damora Therapeutics, Inc. showed an increase of +1717.5% in Cash and Equivalents compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported Stockholders Equity of $240.38 million for fiscal year 2025.
- Damora Therapeutics, Inc. showed an increase of +1418.4% in Stockholders Equity compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported R&D Expense of $26.88 million for fiscal year 2025.
- Damora Therapeutics, Inc. showed an increase of +320.1% in R&D Expense compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported Operating Income of -$210.87 million for fiscal year 2025.
- Damora Therapeutics, Inc. showed a decrease of -847.3% in Operating Income compared to the prior fiscal year.
- Damora Therapeutics, Inc. reported Shares Outstanding of 1.60 million shares for fiscal year 2025.
- Damora Therapeutics, Inc. showed an increase of +21.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: